MPNforum Magazine

Conclusions: The current study identifies imetelstat as an active drug in patients with MF, but also reveals its potential to cause significant myelosuppression. The association between CR/PR and specific mutations suggests potential targeted activity that might be exploited for patient and disease selection.’– Dr. Ayalew Tefferi  from ASH abstract

634 Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Morgan Lam, Geron Project DIrector, Imetelstat

Take me back to the Contents

©  2014, MPNforum, LLC and Zhenya Senyak. Unauthorized use and/or duplication of this material without express and written permission is prohibited. Excerpts and links may be used, provided that full and clear credit is given to MPNforum.com with appropriate and specific direction to the original content. All rights reserved under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.